MX2024004416A - Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. - Google Patents

Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.

Info

Publication number
MX2024004416A
MX2024004416A MX2024004416A MX2024004416A MX2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A MX 2024004416 A MX2024004416 A MX 2024004416A
Authority
MX
Mexico
Prior art keywords
ehmt1
ehmt2
therapeutic use
novel modulators
novel
Prior art date
Application number
MX2024004416A
Other languages
English (en)
Spanish (es)
Inventor
Jon H Come
Joseph P Vacca
Brett Williams
John P Maxwell
Scott Throner
Original Assignee
Tango Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tango Therapeutics Inc filed Critical Tango Therapeutics Inc
Publication of MX2024004416A publication Critical patent/MX2024004416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004416A 2021-10-15 2022-10-14 Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. MX2024004416A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256057P 2021-10-15 2021-10-15
US202263390438P 2022-07-19 2022-07-19
PCT/US2022/046761 WO2023064586A1 (en) 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof

Publications (1)

Publication Number Publication Date
MX2024004416A true MX2024004416A (es) 2024-07-09

Family

ID=84357982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004416A MX2024004416A (es) 2021-10-15 2022-10-14 Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.

Country Status (9)

Country Link
US (1) US20240368139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416143A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024538128A (cg-RX-API-DMAC10.html)
KR (1) KR20240148310A (cg-RX-API-DMAC10.html)
AU (1) AU2022366869A1 (cg-RX-API-DMAC10.html)
CA (1) CA3234693A1 (cg-RX-API-DMAC10.html)
IL (1) IL311999A (cg-RX-API-DMAC10.html)
MX (1) MX2024004416A (cg-RX-API-DMAC10.html)
WO (1) WO2023064586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116602242B (zh) * 2023-05-08 2024-01-23 中国水产科学研究院珠江水产研究所 一种提高反季鱼苗成活率的方法
WO2025155882A1 (en) * 2024-01-19 2025-07-24 Icahn School Of Medicine At Mount Sinai G9a/glp degradation / disruption compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
WO2018195450A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
AU2018353150B2 (en) * 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) * 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies

Also Published As

Publication number Publication date
WO2023064586A1 (en) 2023-04-20
IL311999A (en) 2024-06-01
EP4416143A1 (en) 2024-08-21
AU2022366869A1 (en) 2024-05-02
US20240368139A1 (en) 2024-11-07
CA3234693A1 (en) 2023-04-20
JP2024538128A (ja) 2024-10-18
KR20240148310A (ko) 2024-10-11

Similar Documents

Publication Publication Date Title
WO2020163823A3 (en) Therapeutic agents and methods of treatment
PH12021551409A1 (en) Kif18a inhibitors
MX2021007104A (es) Inhibidores de kif18a.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2024006824A (es) Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2019015468A (es) Moduladores de moleculas pequeñas de sting humana.
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
CA3055791A1 (en) Treatment methods
CR20230408A (es) Compuestos moduladores de gcn2 y usos de los mismos
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2024011254A (es) Moduladores de nlrp3
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
ZA202304965B (en) Combination therapy for treating cancer
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
MX2025005544A (es) Moduladores de gpr17 y sus usos
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2024163641A3 (en) Formulations for treating cancer